99 related articles for article (PubMed ID: 12565723)
1. Effects of activated factor X inhibitor, JTV-803, in a pig model of hemodialysis.
Hayashi M; Uesato N; Aisaka K
Thromb Res; 2002 Sep; 107(6):351-6. PubMed ID: 12565723
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
Hayashi M; Matsuo A; Nakamoto H; Aisaka K
Eur J Pharmacol; 2001 Jan; 412(1):61-6. PubMed ID: 11166737
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of JTV-803, a new cyclic guanidine derivative, on factor Xa in vitro and in vivo.
Hayashi M; Hamada A; Okaya Y; Wakitani K; Aisaka K
Eur J Pharmacol; 2001 Oct; 428(2):163-8. PubMed ID: 11675032
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models.
Asakura H; Ichino T; Yoshida T; Suga Y; Ontachi Y; Mizutani T; Kato M; Ito T; Yamazaki M; Aoshima K; Morishita E; Saito M; Miyamoto KI; Nakao S
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):233-9. PubMed ID: 11943937
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
[TBL] [Abstract][Full Text] [Related]
6. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.
Chi L; Peng YW; Gibson G; Hicks G; Mertz TE; Rapundalo S; Janiczek N; Edmunds JJ; Leadley R
J Cardiovasc Pharmacol; 2004 Oct; 44(4):493-500. PubMed ID: 15454859
[TBL] [Abstract][Full Text] [Related]
9. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
10. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.
Sombolos KI; Fragia TK; Gionanlis LC; Veneti PE; Bamichas GI; Fragidis SK; Georgoulis IE; Natse TA
Int J Clin Pharmacol Ther; 2008 Apr; 46(4):198-203. PubMed ID: 18397694
[TBL] [Abstract][Full Text] [Related]
11. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.
Sato K; Kawasaki T; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Eur J Pharmacol; 1997 Nov; 339(2-3):141-6. PubMed ID: 9473127
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
Suzuki T; Ota K; Naganuma S; Koshikawa S; Hirasawa Y; Nakagawa S; Otsubo O; Akizawa T
Semin Thromb Hemost; 1990 Oct; 16 Suppl():46-54. PubMed ID: 1962904
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
15. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.
Ireland H; Lane DA; Flynn A; Anastassiades E; Curtis JR
Thromb Haemost; 1986 Apr; 55(2):271-5. PubMed ID: 3715791
[TBL] [Abstract][Full Text] [Related]
16. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
[TBL] [Abstract][Full Text] [Related]
17. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]